Arvinas price target lowered to $48 from $60 at Barclays
PremiumThe FlyArvinas price target lowered to $48 from $60 at Barclays
3M ago
Arvinas price target lowered to $50 from $70 at Oppenheimer
Premium
The Fly
Arvinas price target lowered to $50 from $70 at Oppenheimer
4M ago
Arvinas expects cash to fund requirements into 2027
Premium
The Fly
Arvinas expects cash to fund requirements into 2027
4M ago
Arvinas names Andrew Saik as CFO and Treasurer
PremiumThe FlyArvinas names Andrew Saik as CFO and Treasurer
5M ago
Arvinas announces presentations for two PROTAC investigational programs
Premium
The Fly
Arvinas announces presentations for two PROTAC investigational programs
5M ago
Arvinas Announces Key Leadership Appointments in R&D
Premium
Company Announcements
Arvinas Announces Key Leadership Appointments in R&D
5M ago
Oppenheimer remains bullish on Arvinas amid waning enthusiasm over combo data
PremiumThe FlyOppenheimer remains bullish on Arvinas amid waning enthusiasm over combo data
6M ago
Arvinas and Pfizer Breast Cancer Trial Shows Promising Results
Premium
Company Announcements
Arvinas and Pfizer Breast Cancer Trial Shows Promising Results
6M ago
Arvinas,Pfizer update Phase 1b data on vepdegestrant palbociclib combination
Premium
The Fly
Arvinas,Pfizer update Phase 1b data on vepdegestrant palbociclib combination
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100